Abiopharma

QT IMAGING HOLDINGS, INC. (QTI) Reports the reporting period Financial Results QT IMAGING HOLDINGS, INC. (QTI) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 4375
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 10974
  • Continued commercial execution: QT Imaging shipped 15 Breast Acoustic CT scanners during the second quarter of 2026 and 28 scanners during the first six months of the year. The revenue for the second quarter of 2026 was $
  • 4 million. The Company continues to pursue commercial opportunities through a combination of established distribution partners and its expanding internal commercial and business development capabilities.
  • Strengthened capital position: During the second quarter, QT Imaging completed an underwritten public offering that generated approximately $
    • planned for placement at Rambam Health Care Campus, one of the country’s leading academic medical centers. The scanner will support a planned clinical study evaluating Breast Acoustic CT imaging modality in women with hereditary risk for breast cancer, expanding the Company’s clinical evidence-generation efforts in an important high-risk population.•Expanded manufacturing capacity while improving operating efficiency: Continued investing in manufacturing excellence and supply chain readiness while relocating to a new 22,000-square-foot headquarters and manufacturing facility, located in Petaluma, CA. The expanded facility provides more than 2.5x the operational space of the current location while reducing lease cost per square foot by approximately 55%, enhancing the Company's ability to scale production efficiently.•Increased visibility within the investment community: QT Imaging was added to the Russell Microcap® Index as part of the 2026